Fig. 6: Validation of PersonALL, a novel classification approach assigning patients to four prognostic subgroups based on highly individualized cumulative scores reflecting the weighted impact of all detected and prognostically relevant genetic aberrations. | British Journal of Cancer

Fig. 6: Validation of PersonALL, a novel classification approach assigning patients to four prognostic subgroups based on highly individualized cumulative scores reflecting the weighted impact of all detected and prognostically relevant genetic aberrations.

From: PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia

Fig. 6

a Event-free survival of 606 patients with B-cell precursor ALL included in the TARGET ALL Phase 1 Pilot or Phase 2 Expansion studies. Excellent, good, high and ultra-poor risk groups showed an estimated 5-year EFS rate of 93.8%, 87.2%, 70.4% and 52.5%, respectively. b Event-free survival of 866 (260 + 606) patients with B-cell precursor ALL included in the merged discovery (in-house) and validation cohort. Excellent, good, high and ultra-poor risk groups showed an estimated 5-year EFS rate of 94.7%, 87.2%, 69.8% and 46.8%, respectively.

Back to article page